Page 2 - Patients With Metastatic Castration Resistant Prostate Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patients with metastatic castration resistant prostate cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patients With Metastatic Castration Resistant Prostate Cancer Today - Breaking & Trending Today

Dr Sokolova on Talazoparib Plus Enzalutamide in mCRPC

Alexandra Sokolova, MD, discusses key findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer and unanswered questions regarding the use of PARP inhibitors plus androgen receptor inhibitors in patients with biomarker-negative disease. ....

United States , Alexandra Sokolova , Oregon Health Science University , Division Of Hematology Medical Oncology , School Of Medicine , Medical Oncology , Oregon Health , Science University , Cancers Symposium , Talapro 2 Trial , Patients With Metastatic Castration Resistant Prostate Cancer ,

Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPC

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype. ....

United States , San Francisco , Rahul Aggarwal , Clinical Sciences , Helen Diller Family Comprehensive Cancer Center , University Of California , Combination Of Bxcl701 And Pembrolizumab , Patients With Metastatic Castration Resistant Prostate Cancer , Small Cell Neuroendocrine Cancer Phenotype , 2023 Aacr Annual Meeting , Ct03910660 ,

FDA Grants Fast Track Designation to 177Lu-PNT2002 for mCRPC

The FDA has granted a fast track designation to 177Lu-PNT2002 for the treatment of patients with metastatic castration-resistant prostate cancer. ....

Neil Fleshner , Lantheus Holdings , Claude Provost , 177lu Pnt2002 , Patients With Metastatic Castration Resistant Prostate Cancer , Jean Claude Provost , Point Biopharma , Splash Trial ,

CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer. ....

Cyclone 1 Trial , Patients With Metastatic Castration Resistant Prostate Cancer , Cyclone 2 Trial , Cyclone 3 Trial ,